Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 4Neuroblastoma 3Uterine Cervical Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Stomach Neoplasms 1Solid Tumors 1Solid Tumor 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Anus Neoplasms 1Advanced Refractory Solid Tumors 1Advanced Malignant Solid Tumor 1

Interventions

Paclitaxel 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Capecitabine 2nimotuzumab 1lenvatinib 1fludarabine 1cat's claw extract 1TH 302 1Interleukin-2 1Injections 1Infusions, Intravenous 1Gemcitabine 1Drug Evaluation 1Cyclophosphamide 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Solid Tumors × Interleukin-2 × Clear all
NCT05648994 2022-12-13

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Fujian Cancer Hospital

Phase EARLY_PHASE1 Unknown
30 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡